Blincyto is a targeted immunotherapy approved worldwide to treat certain B-cell Acute Lymphoblastic Leukemia (ALL). The incidence of this disease is approximately 1-2 out of 1,00,000 persons. The adult patients suffering from ALL range from 7.3% to 57.8% whereas ALL in children accounts for 19% of childhood cancers in India by 2021.
Mechanism of action
Blincyto works by the concept of BiTE (Bispecific T-Cell Engager) therapy, in which CD19 surface antigens on B cells are targeted. This enables tracking and attacking the malignant cells by engaging T cells (a type of white blood cell that functions in destroying the cells considered enemies). When the T cells are brought in proximity to the cancer cells, these T cells release toxins and induce cancer cell death (apoptosis). Currently, the BiTE therapy is being investigated for its usage in different types of cancers to benefit patients on a larger scale.
Indications
Blincyto is indicated in the treatment of adults and children aged one month and older with:
- CD19-positive B-cell precursor (immature B cell in bone marrow that shows the CD19 marker on its surface) Acute Lymphoblastic Leukaemia (ALL) in first or second complete recovery, along with Minimal Residual Disease (MRD), either greater than or equal to 0.1%.
- CD19-positive B-cell precursor Acute Lymphoblastic Leukaemia (ALL) recurrence or refractory type.
- CD19-positive B-cell Philadelphia chromosome-negative B-cell precursor Acute Lymphoblastic Leukaemia (ALL) in the consolidation phase of multiphase chemotherapy.
Side-effects
The most common side effects in patients taking Blincyto are high temperature, infusion-related reactions, headache, infection, musculoskeletal pain, low neutrophil count, low Red Blood Cell count, low thrombocyte count, and diarrhoea.
Warnings and precautions
- Monitor the patients for infections
- Monitor if the patient shows the symptoms of Pancreatitis
- Follow the instructions as given by the manufacturer for preparation (including admixing) and administration
- Avoid operating heavy or potentially dangerous machinery
- Make sure to use preservative-free saline for children weighing less than 22 kg.
Ordering guide
Blincyto is available as an injection form of 35mcg in a single-dose vial. The blinatumomab availability in India is not authorized , but we help patients to import it in case of their critical need when the doctor advises the patient to buy blincyto India or to import it. We have simplified the ordering process in a step-by-step manner.
1) Order for a Blincyto medicine
You can request a Blincyto on the website and send all the medical history of the patient with a valid prescription for a diagnosed condition.
2) Submission of mandatory Form No. 12
Our team guides you in filing the Form No. 12. Submit a valid prescription from a Registered Medical Practitioner (RMD).
3) Confirmation of the documents
We confirm the documents by verifying the prescription given by a registered healthcare worker, and also the personal ID documents from the patient.
4) Blincyto import
Once the government authorities grant permission from the Drugs Controller General (India), we commence with the importation process.
5) Genuineness of the medicine
Our assigned team makes a note of all the worldwide suppliers and makes the best economic choice.
6) Packaging and distribution of the medicine
Our transport team ensures packaging, labeling, and quality and delivery of the product within the stipulated time.
The blinatumomab price in India is not constant, but we guarantee to provide the medicines at a cost-effective price meeting the international pharmaceutical norms, since it involves legal import channels.
Trust 24/7QualityMeds to access the medicines to patients in medical need with absolute transparency. Our dedicated team is here to manage everything, right from the import to delivery, so that you focus on what matters the most.
Read More Related Blogs: Blinatumomab (Blincyto) in India: Pricing, Import Steps & Access Information
